دورية أكاديمية
أعرض في EDS

Therapeutic and prognostic insights from the analysis of cancer mutational signatures.

التفاصيل البيبلوغرافية
العنوان: Therapeutic and prognostic insights from the analysis of cancer mutational signatures.
المؤلفون: Brady SW; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: samuelw.brady@stjude.org., Gout AM; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA., Zhang J; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: jinghui.zhang@stjude.org.
المصدر: Trends in genetics : TIG [Trends Genet] 2022 Feb; Vol. 38 (2), pp. 194-208. Date of Electronic Publication: 2021 Sep 02.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Trends Journals Country of Publication: England NLM ID: 8507085 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 0168-9525 (Print) Linking ISSN: 01689525 NLM ISO Abbreviation: Trends Genet Subsets: MEDLINE
أسماء مطبوعة: Publication: Cambridge : Elsevier Trends Journals
Original Publication: [Amsterdam, The Netherlands : Elsevier Science Publishers B.V., c1985-
مواضيع طبية MeSH: Neoplasms*/drug therapy , Neoplasms*/genetics, Humans ; Mutation ; Poly(ADP-ribose) Polymerases ; Prognosis
مستخلص: The somatic mutations in each cancer genome are caused by multiple mutational processes, each of which leaves a characteristic imprint (or 'signature'), potentially caused by specific etiologies or exposures. Deconvolution of these signatures offers a glimpse into the evolutionary history of individual tumors. Recent work has shown that mutational signatures may also yield therapeutic and prognostic insights, including the identification of cell-intrinsic signatures as biomarkers of drug response and prognosis. For example, mutational signatures indicating homologous recombination deficiency are associated with poly(ADP)-ribose polymerase (PARP) inhibitor sensitivity, whereas APOBEC-associated signatures are associated with ataxia telangiectasia and Rad3-related kinase (ATR) inhibitor sensitivity. Furthermore, therapy-induced mutational signatures implicated in cancer progression have also been uncovered, including the identification of thiopurine-induced TP53 mutations in leukemia. In this review, we explore the various ways mutational signatures can reveal new therapeutic and prognostic insights, thus extending their traditional role in identifying disease etiology.
Competing Interests: Declaration of interests The authors declare no competing interests.
(Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
References: Nat Cancer. 2021 Aug;2(8):819-834. (PMID: 35122027)
J Clin Oncol. 2016 Mar 20;34(9):910-8. (PMID: 26700127)
Radiat Res. 2010 Dec;174(6):840-50. (PMID: 21128808)
Nat Genet. 2016 Oct;48(10):1131-41. (PMID: 27595477)
Nat Med. 2019 Oct;25(10):1526-1533. (PMID: 31570822)
Nat Rev Genet. 2014 Sep;15(9):585-98. (PMID: 24981601)
Nat Genet. 2014 Feb;46(2):116-25. (PMID: 24413735)
Nat Commun. 2020 Feb 14;11(1):913. (PMID: 32060267)
Nature. 2020 Feb;578(7793):122-128. (PMID: 32025013)
Genome Biol. 2020 Feb 14;21(1):37. (PMID: 32059681)
Nat Commun. 2021 Feb 12;12(1):985. (PMID: 33579957)
Annu Rev Biomed Data Sci. 2021 Jul 20;4:189-206. (PMID: 34465178)
Nat Commun. 2022 May 25;13(1):2926. (PMID: 35614096)
Cancer Res. 2017 Sep 1;77(17):4567-4578. (PMID: 28698210)
EMBO Rep. 2018 Sep;19(9):. (PMID: 30108055)
Nat Commun. 2020 Nov 4;11(1):5584. (PMID: 33149131)
Ann Oncol. 2020 May;31(5):590-598. (PMID: 32245699)
Nat Commun. 2016 May 02;7:11383. (PMID: 27136393)
Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11. (PMID: 25355519)
J Natl Cancer Inst. 2001 Apr 18;93(8):618-29. (PMID: 11309438)
Nat Commun. 2020 Jun 23;11(1):3166. (PMID: 32576827)
Biochem Pharmacol. 1997 Aug 1;54(3):419-24. (PMID: 9278101)
Nat Commun. 2020 Oct 14;11(1):5183. (PMID: 33056981)
Nature. 2015 May 28;521(7553):489-94. (PMID: 26017449)
Nature. 2012 Jun 28;486(7404):537-40. (PMID: 22722843)
Cell Rep. 2015 Nov 10;13(6):1103-1109. (PMID: 26527001)
Nat Commun. 2018 Sep 10;9(1):3667. (PMID: 30202019)
Nature. 2016 May 02;534(7605):47-54. (PMID: 27135926)
Ann Oncol. 2019 Sep 1;30(9):1437-1447. (PMID: 31218365)
Nat Commun. 2015 Apr 23;6:6997. (PMID: 25904160)
Nat Commun. 2018 Aug 17;9(1):3292. (PMID: 30120226)
Nature. 2020 Feb;578(7793):82-93. (PMID: 32025007)
Mutagenesis. 2015 Nov;30(6):763-70. (PMID: 26443852)
Nat Genet. 2015 Dec;47(12):1402-7. (PMID: 26551669)
Clin Cancer Res. 2017 Dec 15;23(24):7521-7530. (PMID: 29246904)
Sci Rep. 2018 Dec 14;8(1):17851. (PMID: 30552369)
Nature. 2019 Apr;568(7753):551-556. (PMID: 30971823)
JAMA Oncol. 2017 Jun 01;3(6):774-783. (PMID: 27768182)
Cancer Cell. 2021 Apr 12;39(4):466-479. (PMID: 33450197)
Trends Biochem Sci. 2010 Sep;35(9):505-13. (PMID: 20430626)
Genome Biol. 2019 Mar 14;20(1):50. (PMID: 30867008)
Nat Rev Cancer. 2021 Oct;21(10):619-637. (PMID: 34316057)
BMC Cancer. 2019 May 15;19(1):457. (PMID: 31092228)
Nature. 2020 Feb;578(7793):94-101. (PMID: 32025018)
Cell. 2019 Mar 7;176(6):1282-1294.e20. (PMID: 30849372)
Nat Genet. 2016 Jun;48(6):600-606. (PMID: 27111033)
Cell Genom. 2022 Nov 09;2(11):None. (PMID: 36388765)
Sci Rep. 2019 Feb 11;9(1):1784. (PMID: 30741997)
Blood. 2009 Jun 11;113(24):6077-84. (PMID: 19224761)
IEEE Trans Pattern Anal Mach Intell. 2013 Jul;35(7):1592-605. (PMID: 23681989)
J Clin Oncol. 2003 Apr 1;21(7):1332-9. (PMID: 12663723)
Nat Genet. 2021 Jul;53(7):1088-1096. (PMID: 34045764)
Cancer Discov. 2021 May;11(5):1082-1099. (PMID: 33408242)
Pharmacogenetics. 1996 Aug;6(4):279-90. (PMID: 8873214)
Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61. (PMID: 23180760)
Genome Biol. 2016 May 09;17:99. (PMID: 27161042)
Mol Cancer Res. 2019 Apr;17(4):895-906. (PMID: 30651371)
Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. (PMID: 29858219)
Cell. 2019 May 2;177(4):821-836.e16. (PMID: 30982602)
Nature. 2020 Apr;580(7804):517-523. (PMID: 32322066)
Nat Genet. 2015 Sep;47(9):1067-72. (PMID: 26258849)
Nature. 2012 Jun 28;486(7404):532-6. (PMID: 22722830)
Genome Med. 2018 Apr 25;10(1):33. (PMID: 29695279)
Nat Commun. 2016 Sep 12;7:12605. (PMID: 27615322)
J Mol Diagn. 2017 Jan;19(1):84-91. (PMID: 27863258)
EBioMedicine. 2017 Jun;20:39-49. (PMID: 28551381)
Oncoimmunology. 2017 Jul 7;6(10):e1346765. (PMID: 29123960)
Blood. 2007 Jul 15;110(2):727-34. (PMID: 17405907)
Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):. (PMID: 33762304)
Cancer Cell. 2010 Jan 19;17(1):77-88. (PMID: 20129249)
Nat Cancer. 2021 Jun;2(6):643-657. (PMID: 34164627)
Nat Genet. 2019 Dec;51(12):1732-1740. (PMID: 31740835)
Cell. 2005 Feb 25;120(4):483-95. (PMID: 15734681)
Blood Cancer J. 2019 Aug 6;9(8):60. (PMID: 31387987)
Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592)
Nat Commun. 2015 Dec 07;6:8866. (PMID: 26638776)
Nat Commun. 2021 Mar 11;12(1):1602. (PMID: 33707442)
Nat Commun. 2018 May 1;9(1):1744. (PMID: 29717121)
Sci Transl Med. 2013 Aug 7;5(197):197ra101. (PMID: 23926199)
Nat Genet. 2018 Oct;50(10):1381-1387. (PMID: 30224644)
Nat Commun. 2020 May 29;11(1):2662. (PMID: 32471999)
Cancer Discov. 2021 Aug;11(8):1923-1937. (PMID: 33837064)
J Natl Cancer Inst. 2000 Jul 19;92(14):1165-71. (PMID: 10904090)
Blood. 2020 Jan 2;135(1):41-55. (PMID: 31697823)
Oncogene. 1998 Nov 5;17(18):2413-7. (PMID: 9811473)
Nat Ecol Evol. 2021 Jul;5(7):1024-1032. (PMID: 34017094)
Genome Biol. 2021 Jan 25;22(1):37. (PMID: 33487172)
Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308)
Genome Res. 2018 May;28(5):654-665. (PMID: 29632087)
Nat Med. 2019 Dec;25(12):1928-1937. (PMID: 31768066)
Science. 2014 Jan 10;343(6167):189-193. (PMID: 24336570)
Nat Med. 2017 Apr;23(4):517-525. (PMID: 28288110)
معلومات مُعتمدة: R01 CA216354 United States CA NCI NIH HHS; R01 CA216391 United States CA NCI NIH HHS
المشرفين على المادة: EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
تواريخ الأحداث: Date Created: 20210906 Date Completed: 20220309 Latest Revision: 20231102
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8752466
DOI: 10.1016/j.tig.2021.08.007
PMID: 34483003
قاعدة البيانات: MEDLINE
الوصف
تدمد:0168-9525
DOI:10.1016/j.tig.2021.08.007